Compare FEIM & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FEIM | PMVP |
|---|---|---|
| Founded | 1961 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 722.9M | 71.1M |
| IPO Year | 1994 | 2020 |
| Metric | FEIM | PMVP |
|---|---|---|
| Price | $85.86 | $1.75 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $95.50 | $4.20 |
| AVG Volume (30 Days) | 309.7K | ★ 515.8K |
| Earning Date | 09-10-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.41 | N/A |
| Revenue | ★ $63,227,000.00 | N/A |
| Revenue This Year | $30.80 | N/A |
| Revenue Next Year | $26.18 | N/A |
| P/E Ratio | $205.98 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $26.05 | $1.02 |
| 52 Week High | $89.76 | $1.88 |
| Indicator | FEIM | PMVP |
|---|---|---|
| Relative Strength Index (RSI) | 60.34 | 68.53 |
| Support Level | $48.49 | $1.05 |
| Resistance Level | $89.68 | $1.88 |
| Average True Range (ATR) | 4.14 | 0.11 |
| MACD | -0.04 | 0.02 |
| Stochastic Oscillator | 52.36 | 89.89 |
Frequency Electronics Inc is a world leader in precision time and frequency generation technology, which is incorporated into commercial and U.S. Government satellites, Command, Control, Communication, Computer, Intelligence, Surveillance and Reconnaissance, and Electronic Warfare systems. Its technology is used for a wide range of space and non-space applications. The company has two segments FEI-NY, and FEI-Zyfer. Majority of revenue come from FEI-NY which provides precision time, frequency generation and synchronization products and subsystems that are found on-board satellites, in ground-based communication systems and imbedded in mobile platforms operated by the U.S. military.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.